- Stable consolidated sales of € 3.6 million (previous year: € 3.7 million) after the first three months
- Maintenance business contribution steady at 42 %
- Earnings before interest and taxes (EBIT) up to € 0.6 million (previous year: € 0.5 million)
- Liquidity risen to € 7.7 million (December 31, 2011: € 7.5 million)
- Strategic reorientation will be communicated by mid-year
Bremen, May 30, 2012 – Today, MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading software provider for the medical imaging market, announced its results for the first quarter of 2012.
Sales came to € 3,637 k, only slightly down on the first quarter of 2011 (€ 3,718 k). License sales declined only marginally by 4 % to € 2,011 k (previous year: € 2,086 k). The maintenance business dropped slightly by 2 %, from € 1,545 k in the extraordinarily successful first quarter of 2011 to € 1,513 k, but rose by 9 % compared to last year’s quarterly average.
Sales in Digital Mammography went down by 8 % compared to an unusually strong prior year quarter (€ 2,876 k) to € 2,650 k. Sales in Other Diagnostics developed positively, rising by 17 % to € 987 k (previous year: € 842 k).
Capitalized development costs fell by 12 % year-on-year to € 691 k (previous year: € 782 k), mainly due to a reduced number of employees but also as a result of the Company’s discontinuing to capitalize development projects written down at the end of 2011.
Personnel expenses dropped considerably by 8 % year-on-year to € 2,298 k (pre-vious year: € 2,510 k) despite a provision for obligations to the former Executive Board member Thomas E. Tynes being recognized. Other operating expenses also decreased by a further 17 % to € 606 k (previous year: € 727 k) as a result of con-tinuing cost savings measures.
Depreciation and amortization came to € 878 k (3 % down year-on-year), resulting in earnings before interest and taxes (EBIT) of € 622 k, clearly up by 22 % on the prior-year figure of € 509 k, as a result of the continuing cost savings measures. The EBIT margin consequently was slightly up year-on-year to 17 % (previous year: 14 %).
The net financial result of € -90 k also increased significantly from € -286 k in the prior-year quarter, one of the contributing factors being earnings developments at the Dutch investment Medis.
Pre-tax earnings rose correspondingly to € 532 k in the period under review (previ-ous year: € 223 k). Taking into account income tax expenses of € 424 k, a figure on par with the previous year and still primarily originating from non-cash deferred taxes, MeVis closed the first quarter of the current fiscal year with consolidated net profit of € 108 k (previous year: € -190 k). Earnings per share therefore amounted to € 0.06 (previous year: € -0.11).
Cash and cash equivalents went up slightly again in the period under review from € 7,506 k as of December 31, 2011 to € 7,749 k as of March 31, 2012.
“We confirm our 2012 forecast, which expected Group sales to stabilize at the same level as in the 2011 fiscal year and EBIT to increase slightly due to an im-proved cost situation following the positive first quarter of 2012.” commented Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG. “We also anticipate positive liquidity from operating activities again in 2012, whereby a purchase price payment of € 3.0 million as part of the acquisition of the 49 % stake in MBS KG will be due for the last time this year, which will have a corresponding impact on liquidity.”
“We have started refocusing our business activities and will conclude our evalua-tion of MeVis’ strategic orientation in the coming weeks,” added Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. “As part of these refocusing measures, we already decided to discontinue our US subsidiary and to gradually transfer its functions to Bremen in the coming weeks and months. We plan to completely close the company by the end of the year at the latest. MeVis’ future strategic orientation will be presented at the annual general meeting on June 12.”
The company`s financial reports are available for downloading at our website.